Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: GlobeNewswire
- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of the global Phase 2 SunStone trial of obexelimab in SLE expected in Q4 2026 - - New, half-life extended anti-CD-19 and Fc?RIIb mAb (ZB014) progressing toward clinical development - - Global orelabrutinib Phase 3 trial for primary progressive multiple sclerosis (MS) ongoing; global Phase 3 trial for non-active secondary progressive MS expected to be initiated in Q1 2026 - - Oral, IL-17AA/AF inhibitor (ZB021) Phase 1 trial expected to be initiated in 2Q 2026 with initial clinical data by year-end - - Up to $250 million non-dilutive, multi-tranche debt financing secured from Pharmakon - WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a le
Show less
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common StockGlobeNewswire
- ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma (ZBIO) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ZBIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" MarketBeat
- Zenas BioPharma (ZBIO) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- Zenas BioPharma (ZBIO) had its price target lowered by Citigroup Inc. from $43.00 to $41.00. They now have a "buy" rating on the stock.MarketBeat
ZBIO
Earnings
- 3/16/26 - Miss
ZBIO
Sec Filings
- 3/26/26 - Form 424B5
- 3/26/26 - Form 424B5
- 3/26/26 - Form FWP
- ZBIO's page on the SEC website